Anuh Pharma cash flow

Latest FY26
Cash from operations
−₹3.0cr₹37.1 cr in FY25
Capital spending
₹7.9cr−60.6% on FY25
Free cash flow
−₹10.9cr₹17.2 cr in FY25
Cash from financing
−₹26.3cr−₹4.9 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—11.48.7
—0.50.6
—−0.6−1.4
—−0.1−0.0
—5.7−4.0
—2.90.3
—−0.4−1.0
—−8.5−2.9
Changes in working capital
—−73.30.9
—−19.9−27.1
—−0.20.1
—9.90.6
—1.4−5.3
—24.017.7
—1.30.6
—2.1−0.6
Cash from operating activities
60.254.261.0
—−44.0−12.8
—10.248.2
—13.211.1
—−3.037.1
Cash from investing activities
—7.920.0
—0.1−0.2
—25.1−1.2
—0.10.0
—0.51.4
—17.8−19.9
Cash from financing activities
—0.08.5
—10.50.0
—0.40.3
—0.50.5
—15.012.5
—−26.3−4.9
—−11.512.4
—−11.512.4
Reference items
64.961.760.9
8.3%8.0%9.2%
−10.9−10.917.2
—−21.9—
−₹1.09−₹1.09₹1.71
—−0.07×0.78×
—13.211.1
—0.50.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ANUHPHR₹79.61

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹798 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation8.711.4—
+ Finance Costs0.60.5—
+ Interest Income-1.4-0.6—
+ Dividend Income-0.0-0.1—
+ Fair Value (Gains) / Losses-4.05.7—
+ Unrealised FX (Gain) / Loss0.32.9—
+ Other Non-cash Items-1.0-0.4—
+ Other — Cash Effects are Investing / Financing-2.9-8.5—
Changes in Working Capital
+ Inventories0.9-73.3—
+ Trade Receivables — Current-27.1-19.9—
+ Other Financial Assets — Current0.1-0.2—
+ Other Financial Assets — Non-current0.69.9—
+ Other Current Assets-5.31.4—
+ Trade Payables — Current17.724.0—
+ Other Financial Liabilities — Current0.61.3—
+ Other Current Liabilities-0.62.1—
Cash from Operating Activities
Profit Before Tax (per I/S)61.054.260.2
+ Total Adjustments (incl. Working Capital)-12.8-44.0—
Cash from Operations (pre-tax)48.210.2—
+ Income Taxes Paid11.113.2—
Cash from Operating Activities37.1-3.0—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)20.07.9—
+ Disp of Fixed Assets-0.20.1—
+ Sale of Investments (Equity / Debt)-1.225.1—
+ Dividends Received — Investing0.00.1—
+ Interest Received — Investing1.40.5—
Cash from Investing Activities-19.917.8—
Cash from Financing Activities
+ Proceeds from Borrowings8.50.0—
+ Repayment of Borrowings0.010.5—
+ Payment of Lease Liabilities0.30.4—
+ Interest Paid0.50.5—
+ Dividends Paid12.515.0—
Cash from Financing Activities-4.9-26.3—
Net Changes in Cash (pre-FX)12.4-11.5—
Net Changes in Cash12.4-11.5—
Reference Items
EBITDA60.961.764.9
EBITDA Margin %9.218.008.32
Free Cash Flow (CFO − Capex)17.2-10.9-10.9
Free Cash Flow to Equity—-21.9—
Free Cash Flow per Basic Share1.71-1.09-1.09
Cash Flow to Net Income0.78-0.07—
Cash Paid for Taxes11.113.2—
Cash Paid for Interest0.50.5—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.